PKP2-ACM
Clinical trials for PKP2-ACM explained in plain language.
Never miss a new study
Get alerted when new PKP2-ACM trials appear
Sign up with your email to follow new studies for PKP2-ACM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy trial hopes to fix heart muscle in rare genetic disease
Disease control OngoingThis early-stage trial tests a gene therapy called LX2020 in 10 adults with a rare, inherited heart condition (PKP2-ACM) that can cause dangerous heart rhythms and heart failure. The therapy is given once through a vein and aims to deliver a working copy of the PKP2 gene to heart…
Matched conditions: PKP2-ACM
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
Gene therapy for rare heart disease: Long-Term safety check begins
Disease control ENROLLING_BY_INVITATIONThis study follows 10 people who already received the experimental gene therapy LX2020 for a genetic heart condition called arrhythmogenic cardiomyopathy. Researchers will monitor them for years to see if the treatment remains safe and continues to work. The goal is to understand…
Matched conditions: PKP2-ACM
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:43 UTC